Skip to main content

Table 3 Clinical trials of combination therapies with molecularly targeted drugs

From: Cancer immunotherapies targeting the PD-1 signaling pathway

PD-1/PD-L1mAb

Combination

Tumor

Reference

PD-1 mAb (Nivolumab)

LAG3 (BMS-986016)

Solid Tumors

NCT01968109

PD-1 mAb (Nivolumab)

B7-H3 (Enoblituzumab)

Solid Tumors

NCT02817633

PD-1 mAb (Pembrolizumab)

B7-H3 (Enoblituzumab)

Solid Tumors

NCT02475213

PD-1 mAb (Nivolumab)

KIR (Lirilumab)

Solid Tumors

NCT01714739

PD-L1 mAb (MEDI4736)

OX40 (MEDI6383)

Solid Tumors

NCT02221960

PD-1 mAb (Nivolumab)

4-1BB (Urelumab)

Solid tumors and B-cell non-Hodgkin lymphoma

NCT02253992

PD-1 mAb (Nivolumab)

ICOS (JTX-2011)

Solid Tumors

NCT02904226

Pd-1 mAb (PDR001)

GITR (GWN323)

Solid Tumors and Lymphomas

NCT02740270

PD-1 mAb (Nivolumab)

CD27 (Varlilumab)

Solid Tumors

NCT02335918

PD-L1 mAb (Atezolizumab)

CD27 (Varlilumab)

Solid Tumors

NCT02543645

PD-1 mAb (Nivolumab)

GM.CD40L (vaccine for NSCLC)

Lung (NSCLC)

NCT02466568

PD-L1 mAb (Atezolizumab)

VEGF inhibitors (Bevacizumab cediranib)

Ovarian Cancer

NCT02659384

PD-L1 mAb (MEDI4736)

PARP inhibitors (Olaparib)

S tumors

NCT02484404

PD-L1 mAb (MEDI4736)

Multi-kinase inhibitor (Sunitinib)

Solid tumors

NCT02484404

PD-1 mAb (Pembrolizumab) with SBRT

Multi-kinase inhibitor (Sunitinib)

TKI refractory mRCCa

NCT02599779

PD-L1 mAb (Durvalumab)

EGFR inhibitor (Osimertinib)

Lung (NSCLC)

reference [70]

  1. a Tyrosine kinase inhibitor refractory metastatic recal cell cancer